RNS Number : 5587J
Arecor Therapeutics PLC
17 August 2023
 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY

 

Arecor expands its global partnerships through collaboration to develop an enhanced antibody formulation

 

Cambridge, UK, 17 August 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs.

 

Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel, stable formulation of a liquid, high concentration antibody.  The collaborator will fund the development work, generating new revenue for Arecor.  This agreement adds to Arecor's growing portfolio of partnerships.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "This collaborator is a leader in the development of novel medicines.  Arecor has a proven track record of leveraging its Arestat technology to help deliver these complex therapeutics.  We work closely with our partners to develop more effective treatments where superior properties bring even greater benefit to patients and we look forward to working with the world-renowned R&D team."

 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

-ENDS-

 

For more information, please contact:

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com



Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

 


Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com



Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

 



Consilium Strategic Communications


Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio

 

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAKPKFSADEFA